Progress in the mechanism of IL-6/STAT3 signaling in mediating resistance to sorafenib in hepatocellular carcinoma
Primary liver cancer(PLC)is one of the most common malignant tumors in China,and hep-atocellular carcinoma(HCC)is its main type.Sorafenib is a new multifunctional oral anticancer drug.As the first multi-target targeted therapy drug approved for clinical application,sorafenib is mainly used for the treat-ment of inoperable or distant metastatic HCC,and is still one of the first-line therapies for HCC.In recent years,patients with liver cancer have developed resistance to sorafenib,while the clinical trials of reducing the resistance of sorafenib combined with other drugs are still at the bottleneck stage.Therefore,exploring the mechanism of sorafenib resistance is of clinical significance for overcoming the resistance of sorafenib in the treatment of PLC.Studies have shown that IL-6/STAT3 signaling pathway plays an important role in the mechanism of sorafenib resistance.In this review,the research progress of the mechanism of drug resistance mediated by IL-6/STAT3 signaling pathway in the treatment of PLC with sorafenib was reviewed,which pro-vided new ideas for solving the problem of drug resistance.
Primary liver cancerSorafenibDrug resistance mechanismInterleukin-6/signal transducer and activator of transcription 3 signaling pathwayReview
国家科技期刊平台
NSTL
万方数据
